Altamira Therapeutics Ltd.
CYTOF
$0.0585
-$0.0115-16.43%
| Weiss Ratings | CYTOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | D- | |||
| Rating Factors | CYTOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | CYTOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.08 | |||
| Price History | CYTOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -27.06% | |||
| 30-Day Total Return | -55.00% | |||
| 60-Day Total Return | -67.50% | |||
| 90-Day Total Return | -86.63% | |||
| Year to Date Total Return | -52.05% | |||
| 1-Year Total Return | -97.20% | |||
| 2-Year Total Return | -99.79% | |||
| 3-Year Total Return | -99.99% | |||
| 5-Year Total Return | -99.98% | |||
| 52-Week High % Change | -97.17% | |||
| 52-Week Low % Change | 34.36% | |||
| Price | CYTOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.47 | |||
| 52-Week Low Price | $0.05 | |||
| 52-Week Low Price (Date) | Apr 03, 2025 | |||
| 52-Week High Price (Date) | May 23, 2024 | |||
| Valuation | CYTOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 326.35K | |||
| Enterprise Value | 688.33K | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -30.42 | |||
| Earnings Per Share Growth | -92.63% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.03 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.06 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -0.18 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | CYTOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 2.06M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CYTOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 441 295 5950 | |||
| Address | -- | |||
| Website | altamiratherapeutics.com | |||
| Country | Bermuda | |||
| Year Founded | 2003 | |||
| Profitability | CYTOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | CYTOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -32.64% | |||
| Return on Equity | -- | |||
| Income Statement | CYTOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -3.92M | |||
| Net Income (TTM) | -4.34M | |||
| Net Income Avl. to Common (TTM) | -4.34M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 4.07% | |||
| EPS Diluted (TTM) | -30.42 | |||
| EPS Diluted Growth (Q YOY) | 92.56% | |||
| Balance Sheet | CYTOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 65.50K | |||
| Cash Per Share (Q) | $0.03 | |||
| Total Current Assets (Q) | 524.00K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 6.32M | |||
| Current Ratio (Q) | 0.427 | |||
| Book Value Per Share (Q) | $2.37 | |||
| Total Assets (Q) | 8.07M | |||
| Total Current Liabilities (Q) | 1.23M | |||
| Total Debt (Q) | 427.40K | |||
| Total Liabilities (Q) | 1.75M | |||
| Total Common Equity (Q) | 6.32M | |||
| Cash Flow | CYTOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 600.00 | |||
| Cash from Financing (TTM) | 2.51M | |||
| Net Change in Cash (TTM) | -668.20K | |||
| Levered Free Cash Flow (TTM) | -1.69M | |||
| Cash from Operations (TTM) | -3.20M | |||
